STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2004 by analyst upside · 2026-06-29
IDXX
IDEXX Laboratories, Inc.
Healthcare · Market Cap $44B · P/E 40.6x
ANALYST PRICE TARGET
+28.6%
implied upside to consensus target
Current Price $551.5
Consensus Target $709.14
Bull Target $805.0
Bear Target $470.0
Analysts Covering 14
ANALYST CONSENSUS - BUY
Strong Buy
4
Buy
5
Hold
5
Sell
0
52-Week Low $506.91
52-Week High $769.98
YTD Return -17.7%
FUNDAMENTALS
Market Cap $44B
P/E Ratio (TTM) 40.6x
Forward P/E 33.4x
EPS (TTM) $13.57
PEG Ratio 3.53
Dividend Yield N/A
Revenue (TTM) $4.4B
Profit Margin 24.6%
52-WEEK RANGE
52-Week Low $506.91
52-Week High $769.98
Current Price $551.5
Bear Target $470.0
Bull Target $805.0
● Now $551.5 ● Target $709.14
TRADING DATA
Avg Volume 622K
YTD Return -17.7%
Analyst Count 14
Consensus Buy
Upside to Target +28.6%
Last Updated 2026-06-29

ANALYST SUMMARY

IDEXX Laboratories, Inc. (IDXX) is currently trading at $551.5 with a Wall Street consensus price target of $709.14, implying potential upside of 28.6% over the next 12 months. 14 analysts currently cover IDXX, with a consensus rating of Buy - 64% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $805.0, while the most cautious has a target of $470.0.

IDXX operates in the Healthcare sector with a market capitalisation of $44B. The stock is down 17.7% year-to-date and is currently trading near the lower end of its 52-week range of $506.91 – $769.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

RECENT ANALYST CALLS

Upgrade/downgrade history for IDXX, with each firm's 90-day track record across all stocks we track. See full firm rankings →

UBS — Reiterated
Neutral → Neutral 2026-04-28 33% win rate (6 calls)
Citigroup ● Initiated
Neutral 2026-04-15 Building track record
Stifel — Reiterated
Buy → Buy 2026-03-31 Building track record
Piper Sandler — Reiterated
Neutral → Neutral 2026-02-09 14% win rate (7 calls)
Barclays — Reiterated
Overweight → Overweight 2026-02-05 Building track record
UBS — Reiterated
Neutral → Neutral 2026-02-03 33% win rate (6 calls)
BTIG — Reiterated
Buy → Buy 2026-02-03 38% win rate (8 calls)
Barclays ● Initiated
Overweight 2025-12-09 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
53
out of 100
Coverage depth
21/30
Consensus clarity
18/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →